文献速递消化系统肿瘤

荷兰1989-2018年罕见直肠恶性肿瘤发病率、治疗与生存的人群研究

The incidence, treatment and survival of patients with rare types of rectal malignancies in the Netherlands: A population-based study between 1989 and 2018.
PubMed 文献 · Eur J Cancer · 2021-06-09

该研究基于荷兰癌症登记1989-2018年88,299例直肠恶性肿瘤,其中2,125例(2.5%)为罕见组织学亚型。直肠神经内分泌肿瘤、肉瘤和腺癌发病率上升,直肠NET预后最好(5年RS 72.4%),直肠黑色素瘤最差(5年RS 8.9%)。2008-2018年直肠腺癌、肉瘤和淋巴瘤生存改善。

要点

  • 罕见直肠恶性肿瘤占2.5%,NET和肉瘤发病率显著上升
  • 直肠NET 5年RS 72.4%,黑色素瘤仅8.9%
  • 2008-2018年腺癌、肉瘤、淋巴瘤生存改善

核心结论

  • 不同罕见类型直肠恶性肿瘤发病率显著上升,且治疗与生存存在差异,可帮助临床医生认识特定疾病。

研究设计与样本

  • 基于荷兰癌症登记1989-2018年诊断的直肠恶性肿瘤患者数据,按RARECARE列表分组,共纳入88,299例,其中2,125例(2.5%)为罕见组织学亚型。

主要发现

  • 直肠神经内分泌肿瘤APC为6.2%(95%CI 5.4%-7.1%),直肠肉瘤APC为5.8%(95%CI 2.9%-8.7%),直肠腺癌APC为1.0%(95%CI 0.26%-1.8%),均呈上升趋势。
  • 直肠NET的5年相对生存率最高,为72.4%(95%CI 70.1%-74.7%);直肠黑色素瘤最低,为8.9%(95%CI 5.1%-15.7%)。
  • 2008-2018年期间,直肠腺癌、直肠肉瘤和直肠淋巴瘤患者的相对生存率改善(p值分别为p<0.001、p=0.023、p=0.029)。

临床怎么用

  • 临床医生应认识罕见直肠恶性肿瘤的发病率变化和预后差异,以便早期识别和个体化处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To describe the incidence, treatment and survival of patients with rare types of rectal malignancies in the Netherlands. METHODS: Data of patients with rectal malignancies diagnosed in the Netherlands between 1989 and 2018 were retrieved from the Netherlands Cancer Registry and grouped according to the RARECARE cancer list. Age-standardised incidence rates were calculated using the European Standard Rate. The Joinpoint Regression Program was used for analysing trends and joinpoints and for the estimation of annual percentage changes (APCs). Patient characteristics, treatment details and relative survival (RS) were reported for different histological types of rectal malignancies and compared between different time periods. RS was assessed using Kaplan-Meier analysis and log-rank test. RESULTS: A total of 88,299 cases of rectal malignancies were included of which 2125 (2.5%) were categorised as rare histological subtypes. The incidence of rectal neuro-endocrine tumours (NET) (APC: 6.2%, 95% confidence interval [CI]: 5.4%; 7.1%), rectal sarcoma (APC: 5.8%, 95% CI: 2.9%; 8.7%) and rectal adenocarcinoma (APC 1.0%, 95% CI: 0.26%; 1.8%) increased. Prognosis was best in patients with rectal NET (5-year RS: 72.4%, 95% CI: 70.1%; 74.7%) and worst in patients with rectal melanoma (5-year RS: 8.9%, 95% CI: 5.1%; 15.7%). RS has improved in patients with rectal adenocarcinoma, rectal sarcoma and rectal lymphoma in 2008-2018 (p-values p < 0.001, p = 0.023 and p = 0.029). CONCLUSION: Significant increases in incidence were observed for different types of rectal malignancies. Differences in incidence, treatment and survival found in this study could be useful to make clinicians aware of specific diseases.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. van Rees JM, Elferink MAG, Tanis PJ, et al. The incidence, treatment and survival of patients with rare types of rectal malignancies in the Netherlands: A population-based study between 1989 and 2018. Eur J Cancer. 2021. PMID: 34118528. doi:10.1016/j.ejca.2021.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。